Legal Representation
Attorney
THOMAS J SPEISS III
USPTO Deadlines
Next Deadline
207 days remaining
Statement of Use Due - Extension 4 Granted
Due Date
February 01, 2026
Extension Available
Until August 01, 2024
Application History
48 eventsDate | Code | Type | Description |
---|---|---|---|
Feb 20, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Feb 19, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED |
Feb 19, 2025 | EXT4 | S | SOU EXTENSION 4 FILED |
Feb 19, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Oct 20, 2024 | EXT3 | S | SOU EXTENSION 3 FILED |
Oct 20, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Oct 20, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED |
Sep 12, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
Sep 12, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Sep 12, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Sep 12, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
Sep 12, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Jun 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Jun 11, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED |
Jun 11, 2024 | EXT2 | S | SOU EXTENSION 2 FILED |
Jun 11, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
May 23, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
May 23, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
May 23, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
May 23, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
May 23, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
Jan 26, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Jan 24, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED |
Jan 24, 2024 | EXT1 | S | SOU EXTENSION 1 FILED |
Jan 24, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Aug 1, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Jun 6, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Jun 6, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
May 17, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
May 2, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
May 1, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
May 1, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
May 1, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
May 1, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
Apr 8, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Apr 7, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Apr 7, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Apr 7, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Oct 7, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Oct 7, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
Oct 7, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
Sep 26, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
Sep 21, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
Jun 8, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Jun 8, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Jun 8, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Apr 20, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Apr 18, 2022 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations, namely, epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; Pharmaceutical preparations, namely, epigenetic drugs targeting arginine methylation in cancer; pharmaceutical preparations in the nature of inhibitors of arginine methylation for the treatment of cancer; pharmaceutical preparations in the nature of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; pharmaceutical compounds for the treatment, diagnosis, detection and prevention of cancer; pharmaceutical preparations for the treatment, diagnosis, detection and prevention of cancer; Pharmaceutical preparations, namely, biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer
Class 042
Research and development services in the pharmaceutical and biotechnology fields; medical research and development services in the pharmaceutical and biotechnology fields; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; consultancy, advisory and information services relating to and connected with the aforementioned services
Additional Information
Other
as to "FASTING MIMICKING"
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"TECHNOLOGY"